PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'MRC Cancer Unit, Hutchison-MRC Research Centre, University of Cambridge, Cambridge, UK.\', \'MRC Cancer Unit, Hutchison-MRC Research Centre, University of Cambridge, Cambridge, UK; Department of Histopathology, Addenbrooke\'s Hospital, Cambridge, UK.\', \'Department of Gastroenterology, Princess Alexandra Hospital NHS Trust, Harlow, UK.\', \'Department of Gastroenterology, East and North Herts NHS Trust, Stevenage, UK.\', \'Department of Surgery, West Suffolk Hospital, Bury St Edmunds, UK.\', \'Department of Gastroenterology, Harrogate District Hospital, Harrogate, UK.\', \'Nottingham Digestive Diseases Centre and NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and University of Nottingham, Nottingham, UK.\', \'Cancer Prevention Group in Clinical Trials Unit, King\'s Clinical Trials Unit, King\'s College London, London, UK.\', \'MRC Cancer Unit, Hutchison-MRC Research Centre, University of Cambridge, Cambridge, UK. Electronic address: rcf29@cam.ac.uk.\']
?:citedBy
  • -1
?:creator
?:doi
  • S1470-2045(21)00667-710.1016/S1470-2045(21)00667-7
?:doi
?:hasPublicationType
?:journal
  • The Lancet. Oncology
is ?:pmid of
?:pmid
?:pmid
  • 35030332
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Use of a Cytosponge biomarker panel to prioritise endoscopic Barrett\'s oesophagus surveillance: a cross-sectional study followed by a real-world prospective pilot.
?:type
?:year
  • 2022

Metadata

Anon_0  
expand all